Radiation oncology firm Accuray is highlighting results from clinical studies featuring its CyberKnife robotic stereotactic body radiation therapy (SBRT) system at the American Association of Physicists in Medicine (AAPM) meeting in Anaheim, CA.
Researchers from UPMC CancerCenter, Erasmus MC Cancer Institute, and European CyberKnife Center Munich shared positive results with the company's InCise multileaf collimator for the CyberKnife M6 system.
In addition, a study conducted at the University of Texas Southwestern Medical Center compared CyberKnife and linac intensity-modulated radiation therapy (IMRT) plans for patients with early-stage larynx cancer. The researchers found that CyberKnife was better able to reduce the radiation dose to normal tissue in high-dose regions, Accuray said.
Finally, a study conducted at Medanta - The Medicity hospital in Gurgaon, India, found that CyberKnife's Multiplan treatment planning system delivered less dose to critical organs than volumetric modulated arc therapy (VMAT) stereotactic plans for patients with localized prostate cancer, according to the firm.
